#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Activated PI3 kinase delta syndrome NTRK gene fusion overexpression Retinal artery occlusion Hodgkin's disease refractory Asthma Hepatoblastoma Oesophageal adenocarcinoma stage III Synovial sarcoma metastatic Chondrosarcoma metastatic Thrombotic thrombocytopenic purpura Aplastic anaemia Glioma Familial hypertriglyceridaemia Progressive supranuclear palsy Pleomorphic liposarcoma More trials…

    Learn about Rare Diseases

    Leukoencephalopathy – Basic Information Mucopolysaccharidosis III Progressive supranuclear palsy – Diagnostics Castleman’s disease – Treatment Sarcoma – Treatment Angiosarcoma metastatic Pemphigus – Trials in Disease Mantle cell lymphoma stage II – Treatment Ocular melanoma – Basic Information Methylmalonic acidaemia – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Hydrocortisone Acetate Ranolazine Crovalimab Ulotaront Fexofenadine Formoterol Fumarate Dihydrate Protrans Raltegravir Epacadostat APAZUNERSEN Etanercept Azetukalner Dinutuximab Beta Human Vaccinia Immunoglobulin Histamine Hydrochloride Sxr1096 Rivaroxaban Vonafexor Imipenem Monohydrate Ampicillin More therapies…

    Learn about Your Condition

    Cystic fibrosis lung Hyperkalaemia Pneumonia chlamydial Encephalitis autoimmune Viral infection Morning sickness Dermatomyositis Coma T-cell type acute leukaemia Bronchitis Pseudoxanthoma elasticum Gouty arthritis Genital herpes Arthralgia Neuroblastoma recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Crohn’s disease

  • Study of mirikizumab and tirzepatide for adults with moderate to severe Crohn’s disease who are overweight or obese

    Recruiting

    3 1
    Investigated Drugs:
    • Mirikizumab
    • Tirzepatide
    Austria Belgium Bulgaria Czechia Denmark France +9

  • A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Guselkumab
    • Risankizumab
    Austria Belgium Czechia Denmark France Germany +7

  • A study of mirikizumab levels in breast milk of breastfeeding women with ulcerative colitis or Crohn’s disease

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Mirikizumab
    Denmark Germany Italy Poland Spain

  • One-Year Effectiveness Study of Guselkumab in Adults with Crohn’s Disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Guselkumab
    France

  • An observational study on the use of methotrexate in children and adolescents with Crohn’s disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Methotrexate
    The Netherlands

  • Using 68Ga-FAPI-46 imaging to detect fibrosis in patients with inflammatory diseases such as Crohn’s disease, ulcerative colitis, systemic sclerosis, and lung fibrosis.

    Recruiting

    2 1 1
    Investigated Diseases:
    • Idiopathic inflammatory myopathy
    • Crohn’s disease
    • Systemic scleroderma
    Investigated Drugs:
    • (S)-2,2′,2”-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
    The Netherlands
1 2 3 … 16
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!